Section Arrow
INCY.NASDAQ
- Incyte Corp
Quotes are at least 15-min delayed:2025/07/20 19:30 EDT
Regular Hours
Last
 67.86
-1.08 (-1.57%)
Day High 
69.43 
Prev. Close
68.94 
1-M High
71.5 
Volume 
1.56M 
Bid
67
Ask
70.8
Day Low
67.8 
Open
69.25 
1-M Low
66.7401 
Market Cap 
13.34B 
Currency USD 
P/E 344.7 
%Yield -- 
10-SMA 68.74 
20-SMA 68.61 
50-SMA 66.49 
52-W High 83.95 
52-W Low 53.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.20/6.91
Enterprise Value
13.38B
Balance Sheet
Book Value Per Share
18.95
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
4.24B
Operating Revenue Per Share
18.64
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 19:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.